Reynders McVeigh Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $24.2M | Buy |
54,310
+974
| +2% | +$434K | 1.21% | 32 |
|
|
2025
Q1 | $25.9M | Buy |
53,336
+1,082
| +2% | +$525K | 1.44% | 30 |
|
|
2024
Q4 | $21M | Buy |
52,254
+3,524
| +7% | +$1.42M | 1.11% | 34 |
|
|
2024
Q3 | $22.7M | Buy |
48,730
+6,269
| +15% | +$2.92M | 1.2% | 32 |
|
|
2024
Q2 | $19.9M | Buy |
42,461
+11,860
| +39% | +$5.56M | 1.13% | 31 |
|
|
2024
Q1 | $12.8M | Buy |
30,601
+14,460
| +90% | +$6.04M | 0.74% | 41 |
|
|
2023
Q4 | $6.57M | Buy |
16,141
+2,070
| +15% | +$842K | 0.42% | 47 |
|
|
2023
Q3 | $4.89M | Buy |
14,071
+4,689
| +50% | +$1.63M | 0.34% | 50 |
|
|
2023
Q2 | $3.3M | Buy |
9,382
+5,410
| +136% | +$1.9M | 0.22% | 57 |
|
|
2023
Q1 | $1.25M | Buy |
3,972
+2,547
| +179% | +$802K | 0.09% | 83 |
|
|
2022
Q4 | $412K | Buy |
+1,425
| New | +$412K | 0.03% | 152 |
|